甘李药业实控人方上周减持85万股 上市5年2募资共33亿

Core Points - Gannee Pharmaceutical recently disclosed a significant change in shareholder equity, with Beijing Xute Hongda Technology Co., Ltd. reducing its stake in the company [1][2] - The equity change period was from April 22, 2025, to April 24, 2025, during which Xute Hongda reduced its holdings by 849,822 shares, representing 0.14% of Gannee's total share capital [1][2] - After the change, Xute Hongda holds 40,634,035 shares, accounting for 6.76% of Gannee's total share capital, while its concerted actor, Gan Zhongru, holds 205,643,757 shares, representing 34.21% [1][2] Company Information - Gan Zhongru is the largest shareholder of Gannee Pharmaceutical, while Xute Hongda is the second largest shareholder [2] - Gan Zhongru has been the controlling shareholder and actual controller of Gannee since 2020, serving as the chairman of the company [2] - Gannee Pharmaceutical was listed on the Shanghai Stock Exchange on June 29, 2020, with an initial public offering (IPO) of 40.2 million shares at a price of 63.32 yuan per share [2][3] Fundraising Activities - Gannee Pharmaceutical raised a total of 2.545 billion yuan through its IPO, with a net amount of 2.441 billion yuan after expenses [2][3] - The funds raised were intended for various projects, including marketing network construction and the registration of insulin products in the U.S. [2] - In 2023, Gannee issued 28,508,550 shares at a price of 27.12 yuan per share, raising approximately 773.15 million yuan, with a net amount of about 759.73 million yuan after expenses [3]